ETIOLOGY, LIFESTYLE FACTORS, AND MODERN MANAGEMENT STANDARDS FOR UTERINE FIBROIDS AND THEIR IMPACT ON PATIENTS' QUALITY OF LIFE: A REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5995Keywords:
Uterine Fibroids, MED12 Mutation, Lifestyle Factors, GnRH Antagonists, Hormonal Fluctuations, Infertility.Abstract
Background: This article is a literature review aimed at providing a comprehensive analysis of the current state of medical knowledge regarding uterine fibroids. The study discusses in detail the etiopathogenetic mechanisms of the condition and highlights the role of lifestyle factors.
Methods: This paper is a narrative review of the current medical literature. A comprehensive literature search was conducted across electronic databases including PubMed, MEDLINE, Embase. Studies included in the analysis comprised randomized controlled trials, cohort studies, clinical guidelines, systematic reviews, and meta-analyses.
Results: Based on the literature review, somatic mutations in the MED12 gene are present in 70–80% of uterine fibroid cases, acting as a primary driver of clonal proliferation. Central obesity, vitamin D3 deficiency, and high red meat consumption stimulate extracellular matrix accumulation. In terms of therapeutics, next-generation oral GnRH antagonists, effectively control heavy menstrual bleeding in 70–80% of patients. Minimally invasive treatments achieve a 40–60% reduction in fibroid volume.
Conclusions: The main conclusion of the paper demonstrates that contemporary treatment of patients with uterine fibroids necessitates abandoning the purely surgical dogma in favor of individualized pharmacological and minimally invasive therapies. Clinical success is no longer evaluated exclusively by the reduction of tumor volume, but by a multidimensional enhancement of the patient’s quality of life and the mitigation of socio-economic costs.
References
Mittal P, Gomez-Lopez N, Mesiano S, et al. The molecular pathogenesis of uterine leiomyomas: A focus on MED12 mutations and epigenetic dysregulation. Human Reproduction Update. 2022;28(4):543-566.
Ali M, Al-Hendy A. Hormonal regulation of uterine fibroids: The critical role of progesterone and estrogen signaling pathways. Steroids. 2021;172:108857.
Islam MS, Ciavattini A, Petraglia F, et al. Extracellular matrix in uterine leiomyoma pathogenesis: A potential target for future therapeutics. Human Reproduction Update. 2023;29(2):211-235.
Ciebiera M, Ali M, Zgliczyński S, et al. The influence of vitamin D on uterine fibroid growth – from molecular mechanisms to clinical practice. Nutrients. 2021;13(8):2712.
Tinelli A, Vinciguerra M, Malvasi A, et al. Dietary habits, obesity, and insulin resistance as modifiable risk factors for uterine leiomyomas. American Journal of Obstetrics and Gynecology. 2022;227(4):591-602.
Piotrowska A, Woźniak K, Zięba M. Endocrine disrupting chemicals (EDCs) and their role in the pathogenesis of uterine fibroids: A systematic review. Environmental Research. 2024;240:117-130.
Grandi G, Facchinetti F, Bitzer J. The impact of regular physical activity and oxidative stress modulation on uterine leiomyoma risk: An epidemiological review. Gynecological Endocrinology. 2023;39(1):2154312.
Al-Hendy A, Lukes AS, Poindexter AN, et al. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. New England Journal of Medicine. 2021;384(7):630-642.
Stewart EA, Lytle BL, Thomas CP. The evolution of modern medical management of uterine fibroids: GnRH antagonists in clinical practice. Fertility and Sterility. 2022;117(5):915-924.
Manyonda I, Belli AM, Lumsden MA, et al. Uterine-Artery Embolization versus Myomectomy for Uterine Fibroids. New England Journal of Medicine. 2020;383(5):440-451.
Verpalen IM, de Boer LM, Linstra ME, et al. High-intensity focused ultrasound (HIFU) for uterine fibroids: Evaluation of safety, efficacy, and quality of life. European Radiology. 2021;31(6):3971-3982.
Spies JB, Coyne K, Guaou Guaou N, et al. Development and validation of a disease-specific quality-of-life questionnaire for uterine fibroids (UFS-QOL). Quality of Life Research. 2002;11(3):263-273.
Borah BJ, Nicholson WK, Bradley L, et al. The societal economic burden of uterine fibroids in the modern era: Absenteeism, presenteeism, and direct healthcare costs. Journal of Women's Health. 2023;32(3):291-301.
Zimmermann A, Bernuit D, Gerlinger C, et al. Prevalence, symptoms and management of uterine fibroids: An international survey on the patient's perspective and quality of life. BMC Women's Health. 2021;21(1):1-11.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Katarzyna Gałan, Weronika Martyna Pielich, Natalia Siusta, Kinga Mehal, Sandra Kuczyńska, Natalia Balicka-Dworczak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
